Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines

US7201907B1 · kind B1 · utility

Assignee

• THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · US

Inventors

• Alexander C. Schmidt · Washington, US
• Mario H. Skiadopoulos · Potomac, US
• Peter L. Collins · Kensington, US
• Brian R. Murphy · Bethesda, US
• Jane E. Bailly · Keyano, CA
• Anna P. Durbin · Takoma Park, US

Key dates

• Filing date: Jun 1, 2000
• Grant date: Apr 10, 2007
• Expiry date: Jun 1, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2810/6072
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response or as vectors for introducing heterologous genes into a host. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different PIV virus to form the human-bovine chimeric PIV genome or antigenome.